sIPV vaccine granted approval for market, pentavalent combination vaccine granted approval for clinical trials
November 25, 2025
Source: drugdu
69
November 24 (NBD AI Express) -- According to an update on China National Biotec Group (CNBG)'s official WeChat account, Wuhan Biological Products Institute, its subsidiary, has recently achieved significant progress in the field of pediatric vaccine development.
The Sabin strain inactivated poliovirus vaccine (Vero cell) has received market approval from the National Medical Products Administration (NMPA) (Approval No.: S20250060). Simultaneously, the Diphtheria, Tetanus, Acellular Pertussis, Inactivated Poliovirus, and Haemophilus Influenzae Type b (Conjugate) Combined Vaccine has obtained clinical trial approval (Acceptance No.: CXSL2500756).
Reference：https://finance.eastmoney.com/a/202511243572908132.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Multiple batches of quadrivalent influenza virus split vaccine have been sub-packaged and submitted for lot release approval; expected to be released to the market soon after approval December 12, 2025
- Ab&B Bio-Tech CO., LTD. JS Lyophilized Human Rabies Vaccine Initiates Phase III Clinical Trials December 12, 2025
- The ‘Sweetest’ HPV Vaccine Market is Gone | Haibin Interview December 12, 2025
- InnoCare Pharma announced that its first independently developed next-generation TRK inhibitor, zoletrazinib, has been approved for marketing in China December 12, 2025
- Is PD-1/VEGF dual antibody + ADC becoming the standard configuration? December 12, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
